OP-687

OP-687 is an investigational oral small-molecule drug being developed by Outpost Medicine for urologic and gastrointestinal disorders, specifically overactive bladder (OAB) and irritable bowel syndrome (IBS). Public information indicates that the compound is positioned as a novel mechanistically targeted therapy for these indications, but detailed target, pharmacology, and chemical class have not been disclosed. OP-687 advanced to at least early clinical development, supported by significant venture financing, with two FDA Investigational New Drug (IND) applications accepted in 2018 for OAB and IBS, but its exact molecular target, modality-specific mechanism, and current clinical phase remain undisclosed or only listed as “pending” in pipeline databases.[1][3][5][7][9][13][15]